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Abstract
Background Coronavirus disease 2019 (COVID-19) disproportionately affects older people. Observational studies suggest 
indolent cardiovascular involvement after recovery from acute COVID-19. However, these findings may reflect pre-existing 
cardiac phenotypes.
Aims We tested the association of baseline cardiovascular magnetic resonance (CMR) phenotypes with incident COVID-19.
Methods We studied UK Biobank participants with CMR imaging and COVID-19 testing. We considered left and right 
ventricular (LV, RV) volumes, ejection fractions, and stroke volumes, LV mass, LV strain, native T1, aortic distensibility, and 
arterial stiffness index. COVID-19 test results were obtained from Public Health England. Co-morbidities were ascertained 
from self-report and hospital episode statistics (HES). Critical care admission and death were from HES and death register 
records. We investigated the association of each cardiovascular measure with COVID-19 test result in multivariable logistic 
regression models adjusting for age, sex, ethnicity, deprivation, body mass index, smoking, diabetes, hypertension, high 
cholesterol, and prior myocardial infarction.
Results We studied 310 participants (n = 70 positive). Median age was 63.8 [57.5, 72.1] years; 51.0% (n = 158) were male. 
78.7% (n = 244) were tested in hospital, 3.5% (n = 11) required critical care admission, and 6.1% (n = 19) died. In fully 
adjusted models, smaller LV/RV end-diastolic volumes, smaller LV stroke volume, and poorer global longitudinal strain 
were associated with significantly higher odds of COVID-19 positivity.
Discussion We demonstrate association of pre-existing adverse CMR phenotypes with greater odds of COVID-19 positivity 
independent of classical cardiovascular risk factors.
Conclusions Observational reports of cardiovascular involvement after COVID-19 may, at least partly, reflect pre-existing 
cardiac status rather than COVID-19 induced alterations.
Keywords Cardiovascular magnetic resonance · Coronavirus disease 2019 (COVID-19) · Severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2)
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Introduction
Coronavirus disease 2019 (COVID-19), which dispropor-
tionately affects older people, is increasingly recognised as 
a multi-system disease [1]. A spectrum of cardiovascular 
manifestations has been reported in the context of acute 
infection [2–8]. The high inflammatory burden of acute 
COVID-19 is postulated to lead to vascular inflammation, 
myocarditis, and cardiac arrhythmias [9–12]. The accom-
panying hypercoagulable state has been linked to higher 
rates of thromboembolic events manifesting as myocardial 
and cerebral infarctions [13].
Interestingly, acute myocardial injury, occurring in the 
context of COVID-19, has been linked to greater mortality 
independent of factors such as acute respiratory distress 
syndrome [5, 6]. Reports of primary cardiac presenta-
tions of COVID-19 in the absence of pulmonary involve-
ment suggest potential cardio-specific actions of severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
[14–16]. Indeed, in vitro studies have demonstrated that 
human cardiomyocytes are permissive for SARS-CoV-2 
infection and that the virus induces a cytotoxic response 
in these cells [17]. Similarly, autopsy studies have dem-
onstrated direct cardiotoxic effects of SARS-CoV-2 [18].
In addition to cardiac involvement linked with acute 
COVID-19, an emerging subset of individuals report a 
protracted disease course with a range of potential cardiac 
symptoms persisting for many weeks after the acute illness 
[19–21]. Limited observational studies have suggested sus-
tained cardiac involvement, based on cardiovascular mag-
netic resonance (CMR) assessment, after recovery from 
acute COVID-19 [22–25]. However, the lack of baseline 
CMR data severely limits any causal interpretation of such 
findings. We, therefore, investigated whether pre-existing 
CMR phenotypes were associated with risk of subsequent 
positive COVID-19 status in the UK Biobank (UKB).
Methods
Setting
The  UK Biobank (UKB) is a very large cohort  study 
incorporating data from over half a million participants 
recruited between 2006 and 2010, designed primarily for 
study of illnesses of middle and older age. Individuals 
aged 40–69 years were identified through National Health 
Service (NHS) registers and recruited via postal invites. 
There was detailed baseline characterisation of partici-
pants including socio-demographics, lifestyle, health sta-
tus, and a series of physical measures [26]. Individuals 
who were unable to consent, or to  complete baseline 
assessment due to illness or discomfort, were not recruited. 
The UKB protocol is publicly available [27]. Linkages 
with hospital episode statistics (HES) and death registers 
allow prospective tracking of health outcomes for all par-
ticipants, documented according to international classifi-
cation of disease (ICD) codes. The UKB has also produced 
algorithmically defined outcomes for key illnesses, such as 
acute myocardial infarction (AMI), which integrate data 
from several sources [28]. The UKB Imaging Study, which 
includes CMR imaging, aims to scan a random subset of 
100,000 participants (> 48,000 completed, January 2021) 
[29]. Linkage with Public Health England permits tracking 
of COVID-19 test results for UKB participants [30, 31].
COVID‑19 tests
We included all UKB participants with CMR imaging and 
COVID-19 testing between 16/03/2020 and 22/08/2020. 
Testing was based on real-time polymerase chain reaction 
(RT-PCR) assay antigen testing. For most participants, the 
sample tested was from combined nose and throat swabs; for 
patients in critical care lower respiratory samples may have 
been used. We considered samples labelled as inpatient to be 
from a hospital setting. Critical care admissions and deaths 
were defined based on HES and death register data.
CMR image acquisition and analysis
CMR imaging was performed in dedicated UKB imaging 
centres using uniform staff training, equipment, and accord-
ing to a previously published protocol [32]. Image analysis 
was performed blind to all participant details using Circle 
Cardiovascular Imaging 42 post-processing software (Ver-
sion 5.11, Circle Cardiovascular Imaging Inc., Calgary, 
Canada). The automated contour detection tool was used 
for analysis of ventricular volumes, LV mass, and LV strain 
(tissue tracking). There was visual quality control (QC) of 
all studies. Those with suboptimal contouring were manually 
corrected by a single reader. Native T1 was calculated from 
a manually drawn septal contour on a mid-ventricular short 
axis slice, excluding cases with poor quality maps or excess 
septal motion. Aortic distensibility (AoD) was calculated 
by dividing aortic strain (change in aortic cross-sectional 
area in diastole to systole) by central pulse pressure (CPP, 
mmHg) [33]. Aortic areas were derived from transverse 
cine images of the aorta using an automated tool previously 
developed and validated in the UKB [34]. The pipeline has 
inbuilt QC, which assigns a probability to correct detection 
of aortic areas. We limited analysis to measurements with 
correct detection probability > 0.75. Aortic contours were 
used to calculate aortic strain at both the ascending and 
descending aorta, which was divided by CPP taken from 
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Vicorder® readings at time of imaging to derive AoD at 
both sites. Thus, the following CMR metrics were consid-
ered: LV/RV volumes in end-diastole and end-systole, LV/
RV stroke volume, LV/RV ejection fraction, LV mass, mid-
ventricular radial strain, mid-ventricular circumferential 
strain, global longitudinal strain (GLS), torsion, septal native 
T1, AoD at the ascending and descending aorta.
Arterial stiffness index
As an additional measure of arterial health in a larger sam-
ple, we considered arterial stiffness index (ASI) derived 
from finger plethysmography [35]. ASI was measured at 
the baseline UKB visit using the PulseTrace PCA2 (Care-
Fusion, USA) device according to a pre-defined protocol 
[36]. Outliers were removed from the ASI variable using 
the Tukey outlier removal method (1.5 × interquartile range 
(IQR) rule), as previously published using this dataset [37].
Statistical analysis
Statistical analysis was performed using R Version 3.6.2 
and RStudio Version 1.2.5019 [38, 39]. Summary descrip-
tive statistics are presented as mean (standard deviation) 
or median [IQR] depending on distribution. We estimated 
the association of each cardiovascular phenotype measure 
with COVID-19 test result (positive vs negative) in logistic 
regression models with adjustment for age, sex, ethnicity, 
deprivation, body mass index (BMI), smoking, diabetes, 
hypertension, high cholesterol, and prior AMI. We present 
odds ratios with corresponding 95% confidence intervals 
(CIs) and p values per unit increase for each cardiac meas-
ure. We performed sensitivity analysis limiting to tests per-
formed in a hospital setting (positive n = 50). In addition, 
owing to the relatively small number of positive cases, we 
re-ran the models using Firth’s penalised logistic regres-
sion [40], which produced near-identical results. Within the 
sample with COVID-19 testing and ASI measurement, we 
tested association of ASI with death and critical care admis-
sion separately in the test positive and negative cohorts with 
multivariable adjustment as before. The results were near 
identical in sensitivity analysis with positive cases defined 
based on RT-PCR and clinical diagnosis of COVID-19 as 
per HES records (ICD10 code H07.2).
Ascertainment of covariates
We took sex as recorded at the baseline UKB visit and age 
at time of COVID-19 testing. We classified ethnicity into 
a binary variable of White and BAME (Black, Asian, and 
minority ethnic) ethnicities. UKB records the Townsend 
score as a measure of material deprivation, with negative 
scores indicating less deprivation than national averages 
[41]. BMI was calculated from height and weight recorded 
at baseline. Smoking status was based on self-report. Hyper-
tension, diabetes, and hypercholesterolaemia were defined 
through cross-checking across self-report and HES data. A 
list of International Classification of Disease (ICD) codes 
used is presented in Supplementary Table 1. Prior AMI 
was obtained from UKB algorithmically defined health 
outcomes.
Ethics
This study was covered by the ethical approval for UKB 
studies from the NHS National Research Ethics Service 
on 17th June 2011 (Ref 11/NW/0382) and extended 10th 
May 2016 (Ref 16/NW/0274). Access to UKB was granted 
through access application 2964. All procedures were per-
formed in concordance with the Declaration of Helsinki.
Results
Characteristics of study participants
There were 315 UKB participants with CMR imaging and 
COVID-19 testing during the defined study period. The 
analysis sample comprised 310 participants (n = 70 posi-
tive) with at least one analysable CMR measure (Fig. 1). Of 
these, 78.7% (n = 244) were tested in hospital, 3.5% (n = 11) 
required critical care admission, and 6.1% (n = 19) died. 
Median age was 63.8 [57.5, 72.1] years; 51.0% (n = 158) 
were male (Table 1). Average interval between CMR and 
COVID-19 testing was 3.0 years. The rates of smoking, 
diabetes, hypertension, high cholesterol, and previous AMI 
were 45.2%, 9.4%, 40.6%, 29.4%, and 3.5%, respectively 
(Table 1). 
Those with a positive test included greater proportions 
of men and BAME individuals than those testing negative 
(Table 1). There were greater number of critical care admis-
sions (5.7% vs 2.9%) and deaths (11.4% vs 4.6%) in the 
COVID-19 positive group, but this was not statistically sig-
nificant. Within the COVID-19 positives, those who required 
critical care admission had higher average rates of all car-
diometabolic morbidities, higher BMI, more deprivation, 
and comprised a greater proportion of men (Supplementary 
Table 2); those who died also had poorer cardiometabolic 
profiles and were older than those who survived. Similar, but 
less pronounced, differences were observed in the COVID-
19 negative group (Supplementary Table 2).
ASI was available for 167,423 participants at baseline, of 
those 6160 had COVID-19 testing within the study period. 
After outlier removal (n = 94), 6066 participants had ana-
lysable ASI, of whom 667 tested positive and 5399 tested 
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negative. The baseline characteristics for this sample are 
summarised in Supplementary Table 3.
Baseline cardiovascular phenotypes
Compared to those testing negative, the COVID-19 positive 
group had, on average, smaller LV end-diastolic volumes, 
smaller stroke volume, lower ejection fraction, and lower 
LV mass (Table 2, Fig. 2). There was a similar pattern in 
the RV measures with smaller volumes in end-diastole and 
end-systole and lower RV stroke volume. COVID-19 posi-
tives had, on average, poorer myocardial deformation by all 
strain measures (circumferential, global longitudinal, radial, 
torsion). They also had, compared to the COVID-19 nega-
tives, slightly higher average native T1 and higher arterial 
compliance (higher AoD, lower ASI); however, there was 
near complete overlap of distributions for these variables 
(Table 2, Fig. 2, Supplementary Table 3).
COVID-19 positive individuals who died had signifi-
cantly lower LV stroke volume, poorer GLS, and lower arte-
rial compliance (lower AoD, higher ASI) compared to those 
who survived (Supplementary Table 4). Those who died in 
the COVID-19 negative group did not have statistically dif-
ferent LV measures compared to those who survived, but 
they did have higher ASI. It is plausible that the associa-
tions with adverse CMR phenotypes may be modified with 
severity of COVID-19. However, we were underpowered to 
definitively test associations with more granular outcomes, 
such as death or critical care admission.
Fig. 1  Approach to selection 
of participants for inclusion in 
the analysis. There were 310 
participants with at least one 
analysable CMR measure, this 
included one participant with 
analysable native T1, but not 
volumetric images. AoD aortic 
distensibility; CMR cardiovas-
cular magnetic resonance; LV 
left ventricle; RV right ventricle; 
SARS-CoV-2 severe acute 
respiratory syndrome corona-
virus 2
UK Biobank participants recruited at 
baseline (2006-2010)
n=502,506
Completed UK Biobank Imaging 
study (2014-2020)
n=48,000 
Tested for SARS-CoV-2 
between 16/3/20 and 22/8/20
n=18,162
CMR scan and SARS-CoV-2 test 
result data available 
n=315




missing images n=4 





missing images n=16 
poor image quality n=5 
poor planning n=1





Pulse wave analysis 
data not available n= 37
Implausible Vicorder 
reading n= 5
Not analysable n= 5
Outlier n= 4
Checks for QC and completeness of 
sequences*
Aging Clinical and Experimental Research 
1 3
Table 1  Characteristics of study 
participants
[a] Welch two sample t test (numeric data with unequal variances); [b] Wilcoxon rank sum test with conti-
nuity correction (numeric skewed); [c] Two-sample test for equality of proportions with continuity correc-
tion (where minimum count > 5); [d] Fisher’s exact test for count data (where minimum count ≤ 5)









Age 63.8 [57.5, 72.1] 65.1 [58.2, 72.1] 61.4 [55.5, 72.4] 0.154 [b]
Sex (male) 158 (51.0%) 117 (48.8%) 41 (58.6%) 0.190 [c]
White 295 (95.2%) 232 (96.7%) 63 (90.0%) 0.049 [c]
BAME 15 (4.8%) 8 (3.3%) 7 (10.0%)
 Asian 8 (2.6%) 5 (2.1%) 3 (4.3%) 0.046 [d]
 Black 2 (0.6%) 2 (2.9%)
 Mixed 3 (1.0%) 2 (0.8%) 1 (1.4%)
 Other 2 (0.6%) 1 (0.4%) 1 (1.4%)
Townsend deprivation score −2.5 [−3.8, 0.2] −2.5 [−3.8, 0.0] −2.4 [−4.1, 0.4] 0.960 [b]
Smoking (current/previous) 140 (45.2%) 108 (45.0%) 32 (45.7%) 1.000 [c]
BMI 27.4 (± 4.9) 27.3 (± 4.7) 27.6 (± 5.6) 0.629 [a]
Diabetes 29 (9.4%) 24 (10.0%) 5 (7.1%) 0.641 [d]
Hypertension 126 (40.6%) 101 (42.1%) 25 (35.7%) 0.414 [c]
High cholesterol 91 (29.4%) 70 (29.2%) 21 (30.0%) 1.000 [c]
Prior myocardial infarction 11 (3.5%) 10 (4.2%) 1 (1.4%) 0.466 [d]
Tested in hospital 244 (78.7%) 194 (80.8%) 50 (71.4%) 0.127 [c]
Critical care admission 11 (3.5%) 7 (2.9%) 4 (5.7%) 0.276 [d]
Death 19 (6.1%) 11 (4.6%) 8 (11.4%) 0.069 [c]
Table 2  Summary of 
Cardiovascular magnetic 
resonance measures
[a] Welch two sample t test (numeric data with unequal variances); [b] Wilcoxon rank sum test with conti-
nuity correction (numeric skewed)
AA ascending aorta; AoD aortic distensibility; COVID-19 coronavirus disease 2019; I denotes indexation 
to body surface area; LVEDV left ventricular endo-diastolic volume; LVEF left ventricular ejection frac-
tion; LVESV left ventricular endo-systolic volume; LVSV left ventricular stroke volume; GLS: global lon-
gitudinal strain; MCS circumferential strain at the mid short axis level; MRS: radial strain at the mid short 
axis level; PDA proximal descending aorta; RVEDV right ventricular endo-diastolic volume; RVEF right 









LVEDVi (ml/m2) 80.0 (± 14.2) 80.8 (± 14.3) 77.1 (± 13.2) 0.046 [a]
LVESVi (ml/m2) 31.5 (± 8.3) 31.6 (± 8.4) 31.4 (± 8.1) 0.863 [a]
LVSVi (ml/m2) 48.5 (± 9.3) 49.2 (± 9.4) 45.7 (± 8.4) 0.004 [a]
LVEF (%) 60.8 (± 6.5) 61.1 (± 6.4) 59.6 (± 6.5) 0.083 [a]
LVMi (g/m2) 46.7 (± 8.8) 46.9 (± 8.8) 45.7 (± 8.4) 0.318 [a]
RVEDVi (ml/m2) 79.2 (± 15.5) 79.9 (± 15.6) 76.9 (± 15.0) 0.148 [a]
RVESVi (ml/m2) 30.8 (± 8.4) 31.0 (± 8.5) 30.0 (± 8.1) 0.393 [a]
RVSVi (ml/m2) 48.4 (± 10.4) 48.9 (± 10.5) 46.8 (± 9.8) 0.133 [a]
RVEF (%) 61.3 (± 6.6) 61.3 (± 6.8) 61.1 (± 6.2) 0.808 [a]
Native T1 (ms) 923.2 (± 39.1) 922.9 (± 40.1) 924.2 (± 35.9) 0.808 [a]
MRS (%) 35.5 (± 9.1) 35.6 (± 9.3) 34.9 (± 8.5) 0.558 [a]
MCS (%) −20.0 (± 3.2) −20.1 (± 3.2) −19.8 (± 3.1) 0.562 [a]
GLS (%) −15.4 (± 2.6) −15.5 (± 2.5) −15.0 (± 2.6) 0.206 [a]
Torsion (degrees) 0.9 (± 0.8) 0.9 (± 0.7) 0.8 (± 1.0) 0.437 [a]
AA AoD (×  10−3  mmHg−1) 1.4 [0.8, 2.3] 1.3 [0.8, 2.3] 1.4 [0.9, 2.3] 0.665 [b]
PDA AoD (×  10−3  mmHg−1) 2.2 [1.7, 3.1] 2.2 [1.7, 3.1] 2.4 [1.6, 3.2] 0.511 [b]
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Association of cardiovascular phenotypes 
with COVID‑19 status
In fully adjusted models, smaller LV and RV volumes in 
end-diastole, lower LV stroke volume, and poorer myocar-
dial deformation by GLS (higher values) were associated 
with significantly higher odds of a positive COVID-19 test 
(Table 3, Fig. 3). Associations with other strain measures, 
torsion, and native T1 were not statistically significant. 
There were no significant associations between measures of 
arterial stiffness (AoD, ASI) and COVID-19 status.
These relationships were unchanged when limiting analy-
sis to the subset of participants tested in hospital (n = 244, 
positive n = 50) and, additionally, there was a significant 
association between smaller RV end-systolic volume and 
higher odds of COVID-19 positivity (Supplementary 
Table 5). In the sample with ASI measurement and COVID-
19 testing (n = 6066), there was no association between ASI 
and death or critical care admission within the COVID-19 




In this sample of 310 UKB participants tested for COVID-
19, we demonstrate association of pre-existing adverse mor-
pho-functional CMR phenotypes with greater likelihood of 
COVID-19 positivity independent of classical cardiovascular 
risk factors. Specifically, in fully adjusted models, smaller 
LV and RV end-diastolic volume, lower LV stroke volume, 
and poorer GLS were associated with significantly higher 
odds of COVID-19 positive test. There were no significant 
associations between arterial stiffness (AoD, ASI) or native 
T1 and COVID-19 status.
Comparison with existing research
Our study is the first to assess association of pre-existing 
cardiovascular phenotypes with subsequent COVID-19 
outcomes.
Fig. 2  Summary of cardiovascular phenotype measures in the 
COVID-19 positive and negative groups. AA AoD aortic distensibility 
at the ascending aorta; ASI arterial stiffness index; CMR cardiovas-
cular magnetic resonance; COVID-19 coronavirus disease 2019; ED 
end-diastole; ES end-systole; GLS global longitudinal strain; MCS 
circumferential strain at the mid short axis level; MRS radial strain 
at the mid short axis level; LV left ventricle; PDA AoD aortic disten-
sibility at the proximal descending aorta. Intervals for AoD show the 
95% confidence interval for the median, all others are 95% confidence 
interval for the mean
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In a cohort of 100 patients recovered from COVID-19, 
Puntmann et al. [23] report significantly larger LV end-
diastolic volumes, lower LV/RV ejection fraction, smaller 
LV mass, higher native T1, higher native T2, and greater 
proportion of late gadolinium enhancement (LGE) abnor-
malities compared to risk factor matched controls. We 
observed similar significant associations between measures 
of poorer LV function (lower LV stroke volume, higher 
GLS) and COVID-19 positivity. However, we found no 
statistically significant association between native T1 and 
COVID-19 status in fully adjusted models. It is possible, 
that associations observed in our study indicate risk factors 
Table 3  Odds ratios from 
logistic regression models 
demonstrating association 
of cardiovascular phenotype 
measures with COVID-19 status
Modelling is with sample tested for COVID-19 with analysable CMR data. Model outcome is set as 
COVID-19 test result (positive vs negative). Fully adjusted model includes adjustment for age, sex, ethnic-
ity, deprivation, body mass index, smoking, diabetes, hypertension, high cholesterol, and prior myocardial 
infarction. Results are odds ratio [95% confidence interval] and p value, each belonging to a separate logis-
tic regression model with covariate adjustment as indicated in columns
AA ascending aorta; AoD aortic distensibility; ASI arterial stiffness index; COVID-19 coronavirus disease 
2019; LVEDV left ventricular endo-diastolic volume; LVEF left ventricular ejection fraction; LVESV left 
ventricular endo-systolic volume; LVSV left ventricular stroke volume; GLS global longitudinal strain; 
MCS circumferential strain at the mid short axis level; MRS radial strain at the mid short axis level; PDA 
proximal descending aorta; RVEDV right ventricular endo-diastolic volume; RVEF right ventricular ejec-
tion fraction; RVESV right ventricular end-systolic volume; RVSV right ventricular stroke volume
Univariate Age and sex adjusted Fully adjusted
LVEDVi (ml/m2) 0.98 [0.96, 1.00] 0.97* [0.95, 0.99] 0.97* [0.95, 1.00]
0.057 8.50 ×  10−3 0.022
LVESVi (ml/m2) 1.00 [0.96, 1.03] 0.99 [0.95, 1.02] 1.00 [0.96, 1.03]
0.865 0.416 0.806
LVSVi (ml/m2) 0.96* [0.93, 0.99] 0.95* [0.92, 0.98] 0.95* [0.92, 0.98]
6.4 ×  10−3 1.4 ×  10−3 2.2 ×  10−3
LVEF (%) 0.96 [0.93, 1.00] 0.97 [0.93, 1.01] 0.96 [0.91, 1.00]
0.081 0.127 0.059
LVMi (g/m2) 0.98 [0.95, 1.02] 0.96* [0.92, 1.00] 0.96 [0.92, 1.00]
0.328 0.036 0.087
RVEDVi (ml/m2) 0.99 [0.97, 1.00] 0.98* [0.96, 1.00] 0.98* [0.96, 1.00]
0.155 0.023 0.042
RVESVi (ml/m2) 0.99 [0.95, 1.02] 0.96* [0.92, 1.00] 0.97 [0.93, 1.00]
0.404 0.050 0.087
RVSVi (ml/m2) 0.98 [0.95, 1.01] 0.97 [0.95, 1.00] 0.98 [0.95, 1.00]
0.146 0.065 0.093
RVEF (%) 1.00 [0.96, 1.04] 1.01 [0.97, 1.06] 1.01 [0.96, 1.06]
0.816 0.682 0.746
Native T1 (ms) 1.00 [0.99, 1.01] 1.00 [1.00, 1.01] 1.00 [1.00, 1.01]
0.818 0.536 0.483
MRS (%) 0.99 [0.96, 1.02] 1.00 [0.97, 1.04] 1.00 [0.96, 1.03]
0.575 0.828 0.972
MCS (%) 1.02 [0.94, 1.11] 0.99 [0.90, 1.09] 1.01 [0.91, 1.11]
0.569 0.914 0.851
GLS (%) 1.07 [0.96, 1.19] 1.10 [0.98, 1.24] 1.14* [1.01, 1.29]
0.197 0.113 0.039
Torsion (degrees) 0.86 [0.62, 1.20] 0.88 [0.63, 1.24] 0.92 [0.65, 1.31]
0.366 0.443 0.628
AA AoD (×  10−3  mmHg−1) 1.06 [0.84, 1.33] 0.93 [0.68, 1.23] 0.92 [0.67, 1.24]
0.602 0.625 0.606
PDA AoD (×  10−3  mmHg−1) 1.12 [0.89, 1.41] 1.04 [0.79, 1.35] 1.06 [0.79, 1.39]
0.372 0.863 0.812
ASI (m/s) 0.99 [0.96, 1.02] 0.99 [0.96, 1.02] 0.99 [0.96, 1.02]
0.367 0.549 0.481
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for symptomatic COVID-19, whilst the findings of Punt-
mann et al. [23] reflect alterations occurring after COVID-
19. These different observations may also reflect different 
approaches to confounder adjustment. In our study, we 
consider a wider range of potential confounders, including, 
ethnicity, BMI, deprivation, and high cholesterol (in addition 
to all factors matched by Puntmann et al. [23]). Further-
more, our COVID-19 negative cohort comprise individuals 
tested for COVID-19, mostly in hospital (80.8%); therefore, 
these participants are likely to have been admitted with an 
acute illness, possibly with respiratory symptoms, during 
the same time period. The control subjects in Puntmann 
et al. [23] were not hospitalised or tested for COVID-19. 
Overall, our comparator cohort was more appropriately 
matched to the COVID-19 positive cases with considera-
tion of a wider range of confounding variables. Therefore, 
some of the changes observed by Puntmann et al. [23], may 
be compromised by residual confounding. It is also possible 
that our study is underpowered to detect small associations 
with native T1.
Knight et al. [42] present a retrospective review of 29 
individuals hospitalised with COVID-19, referred for CMR 
post-recovery with unexplained myocardial injury (elevated 
troponin) during the acute illness. Their participants had 
moderate-severe presentations of COVID-19, with over a 
third requiring intensive care and ventilatory support. There 
were non-ischaemic ("myocarditis-like")  and ischaemic 
LGE patterns of myocardial injury in 13 and 2 participants, 
respectively. Interestingly, patients with "myocarditis-like" 
LGE did not have higher T2 (myocardial oedema) than the 
rest of the cohort, suggesting that either the observed myo-
cardial alterations are fixed post-COVID-19 changes or that 
they pre-existed the infection. In a similar study, Huang 
et al. [25] report CMR findings from patients recovered from 
COVID-19 with ongoing cardiac symptoms. They present 
three-way and cross-group comparisons between patients 
with COVID-19 and positive CMR findings (defined as ele-
vated T2 or presence of LGE, n = 15), COVID-19 and nega-
tive CMR findings (n = 11), and healthy controls (n = 20). 
They do not report any significant differences in LV volu-
metric or functional parameters. Compared to healthy con-
trols, CMR positives had significantly poorer RV function 
by ejection fraction, stroke volume, and cardiac output. They 
report higher global native T1 in three way comparison, and 
when comparing CMR positives to healthy and CMR nega-
tive cases, but not when comparing CMR negatives with 
healthy controls. The CMR positive group had higher global 
T2 and extracellular volume (ECV) compared to healthy 
cohorts. As the researchers pre-select known abnormal 
cases (CMR positives) to compare with known normal cases 
(healthy comparators or CMR negatives), it is difficult to 
reliably compare these findings with those from our study.
Rajpal et al. [24] and Clark et al. [22] report CMR find-
ings of young athletes (mean age 19.5 and 20.0  years, 
respectively) recovered from mild/asymptomatic COVID-
19. Rajpal et al. [24] present a descriptive report of 26 
Fig. 3  Odds ratios from fully adjusted multivariable logistic regres-
sion models demonstrating association of cardiovascular phenotype 
measures with COVID-19 status. Association of each cardiovascular 
measure with COVID-19 test result (positive vs negative) in multi-
variable logistic regression models adjusting for age, sex, ethnicity, 
deprivation, body mass index, smoking, diabetes, hypertension, high 
cholesterol, and prior myocardial infarction. Results are from individ-
ual models and expressed as odds ratio and 95% confidence interval 
(CI) corresponding to each cardiovascular measure. Green: 95% CI 
includes one. Red: 95% CI does not include one
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college athletes, reporting non-ischaemic patterns of LGE 
in 12 participants, of whom, four also had elevated T2. Clark 
et al. [22] compare CMR metrics of 22 college athletes with 
22 healthy controls and 22 tactical athletes. The COVID-
19 positive group had significantly larger RV volumes and 
lower RV ejection fraction compared to both control groups. 
The results of parametric mapping indices showed no sig-
nificant difference in native T1 between the groups, higher 
T2 in cases vs healthy controls, and higher ECV in cases vs 
tactical athletes, but not healthy controls. LGE was seen in 
two cases, the comparator groups did not have LGE imag-
ing for comparison. It is possible that the observed changes 
related to athletic cardiac adaptation. Indeed, many of the 
volumetric and parametric mapping difference reported by 
Clark et al. [22] were less pronounced when comparing 
COVID-19 positive athletes to tactical athletic controls than 
healthy controls. Overall, interpretation of these non-specific 
CMR findings in these rather atypical populations is chal-
lenging, particularly as the participants had no symptoms or 
biochemical evidence of myocardial injury.
In a large multi-centre survey-based study, Dweck et al. 
[7] report echocardiographic findings from 1216 patients 
with acute COVID-19 and clinical indication for echocar-
diography performed in hospital. In patients without pre-
existing cardiac disease, LV abnormalities were noted in 
25% and RV abnormalities in 33%. Those with an abnormal 
scan were older and had higher prevalence of pre-existing 
disease. RV abnormalities were more common in patients 
with more severe COVID-19 and likely reflect elevations 
in RV afterload due to pulmonary embolism or pneumonia. 
LV abnormalities were predominantly non-specific, a few 
cases showed patterns consistent with myocardial infarc-
tion (3%), myocarditis (3%), or Takotsubo cardiomyopa-
thy (2%). Mahmoud-Elsayed et al. [3] report similar find-
ings in a single centre study of hospitalised patients with 
COVID-19 pneumonia. In this sample, as per Dweck et al. 
[7], RV abnormalities dominated, likely secondary to pul-
monary pathology rather than cardiac involvement. Indeed, 
RV systolic dysfunction was significantly associated with 
elevated D-dimer and C reactive protein levels but not with 
high sensitivity Troponin I. In this cohort, LV systolic func-
tion was hyperdynamic or normal in most cases (89%); 11% 
had impaired LV systolic function and 4% had a dilated LV. 
These findings likely reflect changes in cardiac phenotypes 
occurring secondary to the acute COVID-19 illness, but 
also, perhaps cardiac features that predispose to sympto-
matic COVID-19; acute cardiac abnormalities that may have 
occurred due to COVID-19 appear to be uncommon and 
poorly defined with echocardiography.
Clinical implications
Our findings demonstrate association of smaller LV and RV 
end-diastolic volume, lower LV stroke volume, and poorer 
GLS were with significantly higher odds of COVID-19 
positive test. Overall, this pattern of associations presents 
the picture of a cardiac phenotype with poorer myocardial 
contractility and smaller stiffer ventricles. This suggests 
that adverse cardiac phenotypes, perhaps resembling a 
heart failure preserved ejection fraction (HFPEF) pheno-
type, are associated with greater odds of COVID-19. The 
magnitude of differences observed is small and, at the indi-
vidual level, their clinical significance is highly uncertain. 
However, given the massive population burden of COVID-
19, small effects in large number of people are likely to be 
important. Our findings of significant associations between 
pre-existing adverse CMR phenotypes and incident COVID-
19 suggest that reports of long-term cardiac involvement of 
COVID-19 based on study of post-recovery CMR imaging 
may be hampered by residual confounding and reverse cau-
sation and that observed differences in CMR metrics in these 
studies may, at least partly, reflect pre-existing cardiac status 
rather than new COVID-19 related changes.
Strengths and limitations
In the present study, we used a well-defined cohort, with 
CMR imaging performed according to uniform techni-
cal protocols, linked to national COVID-19 test results. 
Uniquely, imaging in this study preceded COVID-19 testing 
by 1–6 years. As a result, our findings add a new and impor-
tant perspective to existing work, which exclusively relies on 
imaging performed after COVID-19 testing. The availability 
of data from a hospitalised COVID-19 negative cohort pro-
vided an appropriate comparator cohort. In the present study, 
case definition was based on SARS-CoV-2 RT-PCR. In prac-
tice, patients may be diagnosed with COVID-19 based on 
clinical presentation and investigations in the absence of a 
positive PCR test. However, misclassification of cases in our 
analysis would lead to a conservative bias if anything, and 
indeed in a sensitivity analysis including RT-PCR and clini-
cally defined cases, our results were unchanged. Within the 
COVID-19 positive cohort, there were eight deaths and four 
critical care admissions, as such, we had very limited ability 
to discern whether baseline cardiac phenotypes were related 
to disease severity. Future analyses with greater numbers 
of events will be required to clarify this point. Whilst is it 
plausible that baseline cardiac phenotype might be associ-
ated with risk of symptoms that might occasion COVID-19 
testing, it is unlikely that this would influence our findings 
since UK testing is limited to symptomatic SARS-CoV2 
infection (indeed at the time of our analysis predominantly 
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disease severe enough to require hospital admission), and 
we compared populations according to test result within the 
tested population. However, our results should be interpreted 
in the context of the more severe spectrum of COVID-19 
manifestations and may not apply across milder or asymp-
tomatic disease manifestations. Furthermore, due to the 
observational nature of the study, we cannot exclude residual 
confounding or infer causality.
Conclusions
Our results, in a predominantly hospitalised cohort, demon-
strate that several pre-existing adverse cardiac phenotypes 
are associated with greater risk of incident COVID-19, sug-
gesting that these phenotypes may be risk factors for, rather 
than outcomes of, SARS-CoV-2 infection. Thus, observa-
tional reports of cardiovascular involvement after COVID-
19 may, at least partly, reflect residual confounding and/or 
reverse causation from pre-existing cardiac status rather than 
COVID-19 induced alterations. However, whilst volumet-
ric and ventricular function measures appeared dominant 
in our analysis, differences in tissue characteristics were 
more pronounced in studies reporting CMR phenotypes 
after COVID-19 infection. Thus, it is possible that whilst 
some adverse cardiac phenotypes pre-dispose to more severe 
COVID-19 and need for hospitalisation, SARS-CoV-2 infec-
tion itself might also lead to distinct phenotypic alterations. 
Further research in larger populations, with appropriate con-
trol groups and ideally imaging before and after COVID-19 
disease, together with prospective follow-up, are required 
for definitive conclusions.
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